Famotidine (Pepcid)
H2 receptor antagonist that reduces stomach acid production. Faster onset but shorter duration of action compared to proton pump inhibitors.
Projected serum levels — 20 mg, twice daily
Maintenance schedule: 20 mg twice daily (oral).
Modeled steady state after ~1 days: peak ≈ 6.2 mg, trough ≈ 0.80 mg body load. Population-based estimate over 15 days for a 20 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- H2 Blocker
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 3 h
- Common dose
- 20 mg
- Suggested maximum
- 80 mg/day
- Reference dose range
- 10–80 mg (single dose)
- Suggested cadence
- twice daily
- Validated against
- 40 mg oral — Cmax 0.085 mg/L at 2 h
Documented interactions
-
caution
Iron (Bisglycinate) + Famotidine (Pepcid)
H2 blockers reduce gastric acid needed for non-heme iron absorption.
-
caution
Itraconazole (Sporanox) + Famotidine (Pepcid)
Famotidine (Pepcid) raises gastric pH, which may reduce absorption of Itraconazole (Sporanox) (antifungal — requires gastric acid for dissolution).
-
caution
Levothyroxine (Synthroid) + Famotidine (Pepcid)
Famotidine (Pepcid) raises gastric pH, which may reduce absorption of Levothyroxine (Synthroid) (thyroid hormone — absorption pH-dependent).
-
caution
Mycophenolate Mofetil (CellCept) + Famotidine (Pepcid)
Famotidine (Pepcid) raises gastric pH, which may reduce absorption of Mycophenolate Mofetil (CellCept) (immunosuppressant — dissolution pH-dependent).
-
caution
Rilpivirine (RPV / Edurant) + Famotidine (Pepcid)
Famotidine (Pepcid) raises gastric pH, which may reduce absorption of Rilpivirine (RPV / Edurant) (NNRTI — absorption reduced at elevated pH).
-
caution
Vitamin B12 (Cobalamin) + Famotidine (Pepcid)
H2 blockers reduce stomach acid, impairing B12 liberation from food. Less severe than PPIs but still relevant long-term.
Serum checks 8 modeled interaction pairings for famotidine (pepcid) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Famotidine, a new H2-receptor antagonist: a review of preclinical and clinical studies
Foundational review establishing famotidine as 20-50 times more potent than cimetidine at the H2 receptor, with excellent safety profile and once or twice daily dosing.
-
Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study
Retrospective study of hospitalized COVID-19 patients found famotidine use was associated with reduced risk of clinical deterioration, intubation, or death.
-
Comparison of famotidine with ranitidine for treatment of patients with gastric or duodenal ulcers
Multicenter trial found famotidine 40 mg at bedtime was as effective as ranitidine 150 mg twice daily for healing gastric and duodenal ulcers.
3 published studies referenced in the app, each with a plain-language summary.